International Journal of Multidisciplinary and Innovative Research

ISSN(print): 3050-6883, ISSN(online): 3050-6891

Volume 03 Issue 08 August 2026

DOI: 10.58806/ijmir.2026.v3i8n06

Page No: 682-688

Navigating Quality, Safety, and Analytical Testing Frameworks for Viral Vector–Based Gene Editing Therapies

Yusra A. Radeef[1]*, Zahraa Ali Abdullah[2], Eman Fadhel Abbas Awadh[3]

[1,2,3]Department of Biology, College of Science, Babylon University, Iraq

ABSTRACT

Viral vectors have become the backbone of delivery strategies in modern gene therapy, offering biologically robust means of transporting therapeutic transgenes and genome-editing machinery, most notably CRISPR-Cas nuclease systems, into target cells. Moving these intricate macromolecular assemblies from bench-scale research into human clinical application, however, is far from straightforward: it raises substantial analytical, manufacturing, and safety questions that cannot be resolved through conventional characterization alone. Meeting international regulatory expectations demands the establishment of harmonized, multi-layered quality control systems spanning every stage of vector production. This review takes a critical look at the analytical approaches currently used to characterize viral delivery platforms, with particular attention to recombinant adeno-associated viruses (rAAV), lentiviruses, and adenoviruses. We examine the core quality attributes that define these products—genome titer determination, ratios of physical to infectious particles, discrimination between empty and full capsids, and quantification of residual host-cell proteins and host-derived nucleic acids—and consider how well existing assays actually capture these properties in practice. Beyond product characterization, we turn to nuclease-associated safety concerns, reviewing the methods available for detecting unintended double-strand breaks at off-target sites, structural rearrangements within the genome, and the emergence of replication-competent viral variants. By weighing what current technologies can reliably achieve against their practical limitations, this article aims to provide a working framework for verifying the potency, genomic integrity, and clinical safety of vector-based gene therapies—one intended to be useful both to laboratories developing these products and to those responsible for regulating them.

ARTICLE DETAILS

Published On:
18 August, 2026

KEYWORDS: Viral vectors; gene editing; CRISPR-Cas9; analytical testing; biosafety profiling; quality control; off-target cleavage; vector titration.

Available on:
https://ijmir.com

1. INTRODUCTION

1.1 The Evolution of Targeted Genetic Therapeutics

Molecular medicine has moved through a genuine paradigm shift over the past two decades, gradually leaving behind the earlier model of non-specific gene supplementation in favor of precise, site-directed genomic editing (1,2). For much of its history, gene therapy relied on a fairly straightforward logic: deliver a functional copy of a gene to compensate for a defective one already present in the patient's cells (1). This additive approach proved reasonably effective for a subset of monogenic recessive conditions, yet it falls short when the underlying problem involves a dominant-negative mutation, a polygenic trait, or a defect requiring correction at a specific genomic locus rather than simple supplementation (1,4).

The emergence of programmable nuclease platforms—CRISPR-Cas systems being the most prominent example—has meaningfully broadened what genetic medicine can accomplish (2,4). These tools work by introducing double-strand breaks, single-strand nicks, or targeted base edits at defined genomic coordinates, which in turn allows researchers to repair, disrupt, or fine-tune gene expression directly at the source rather than working around it (2,14). Translating this molecular precision into viable clinical treatments, though, still hinges on solving two stubborn problems: getting these editing tools efficiently into cells within a living organism, and building analytical quality systems rigorous enough to satisfy both scientific and regulatory scrutiny (3,15).

1.2 Viral Vectors as Primary Delivery Vehicles

Non-viral delivery technologies—lipid nanoparticles and engineered polymer-based carriers among them—have made real progress in recent years, but recombinant viral vectors continue to dominate clinical gene transfer. This is largely because viruses have spent millions of years evolving the very capabilities gene therapy needs: efficient cell entry, nuclear trafficking, and reliable gene expression (1,3,11). That said, no single viral platform does everything well, and the choice of vector typically comes down to a set of trade-offs specific to the clinical context:

Recombinant Adeno-Associated Viruses (rAAV): Favored for in vivo delivery to differentiated tissue, largely because they provoke a comparatively mild immune response, rarely integrate into the host genome, and can sustain long-term episomal gene expression in non-dividing cells (1).

Lentiviruses and Retroviruses: Better suited to ex vivo applications—hematopoietic stem cell modification and CAR-T cell manufacturing being the clearest examples—since their capacity for stable genomic integration ensures the therapeutic cassette is faithfully passed on through subsequent cell divisions (3).

Adenoviruses: Valued for their rapid transduction and comparatively large packaging capacity, which makes them a practical choice for applications where transient expression is sufficient, including localized gene delivery and vaccine platforms (11).

Packaging CRISPR-Cas components—the sizable open reading frames encoding endonucleases like Cas9 or Cas12a, together with the single-guide RNA elements that direct them—adds a further layer of engineering constraint (4). Vector design in this context is shaped as much by cargo size limits and promoter choice as by the intended tissue target, and these constraints collectively narrow the practical design space for effective genome editing (3,4).

1.3 Analytical and Biosafety Requirements

As viral vectors have shifted from passive carriers of therapeutic genes to active platforms delivering genome-editing enzymes, the level of regulatory scrutiny applied to their characterization and safety profile has risen accordingly (15). Pairing a viral delivery system with an active nuclease payload compounds the associated risks, which is why comprehensive, multi-pronged testing is required before any such product can move into clinical use (6,8):

Vector Purity and Physical Integrity: This involves accurately distinguishing full, partially filled, and empty capsids, determining total vector genome titer, and quantifying residual impurities carried over from the production process, including host-cell proteins and DNA (6,8).

Replication Competency: Manufacturers must demonstrate the complete absence of replication-competent particles—such as rcAAV or RCL—that can arise unintentionally through homologous recombination events during vector production (13).

Off-Target Cleavage and Structural Aberrations: Testing must also capture unintended nuclease activity at non-target genomic sites, along with large-scale deletions or chromosomal translocations that can result from prolonged Cas enzyme activity within the cell (8,9).

Host Immunogenicity: Finally, both cellular and antibody-mediated immune responses to capsid proteins or to the foreign nuclease itself need to be characterized (3,7).

Establishing consistent, standardized analytical frameworks is therefore not merely a regulatory checkbox—it is fundamental to ensuring that these products behave consistently from batch to batch and remain safe for the patients who receive them (6,15). The sections that follow examine the principal analytical strategies currently used to evaluate viral vector preparations, whether they carry conventional therapeutic transgenes or active CRISPR-based editing components (6,15).

2. LITERATURE REVIEW METHODOLOGY

Given how broad the analytical and biosafety landscape surrounding viral vector-mediated gene editing has become, this work adopts a structured narrative review approach rather than a fully systematic one (11). When guided by a clearly defined search protocol, narrative reviews of this kind strike a workable balance between breadth and interpretive depth—they allow for systematic engagement with peer-reviewed literature, standard analytical protocols, and regulatory documentation without forcing the discussion into an overly rigid framework that this particular subject does not always accommodate well (11,15).

2.1 Database Search Strategy

Literature searches were conducted across four major bibliographic databases: PubMed/MEDLINE, Web of Science, Scopus, and Google Scholar. These were chosen because, taken together, they provide reasonably comprehensive coverage of biomedical, translational, and regulatory science literature (11). Priority was given to peer-reviewed original research, methodological reports, and formal guidance documents issued by the FDA and the EMA, given that these agencies play the central role in defining current analytical and safety expectations for gene therapy products (11,15).

Search terms were built using Boolean operators (AND/OR) in combination with Medical Subject Headings (MeSH) and terminology specific to the field. The search strategy was organized around four conceptual domains:

Vector delivery systems — ("Viral vectors" OR "Adeno-associated virus" OR "AAV" OR "Lentivirus" OR "Adenovirus")
Genome editing payloads, combined via AND — ("CRISPR-Cas9" OR "Precision gene editing" OR "Base editing" OR "Transgene delivery")
Analytical quality control, combined via AND — ("Analytical testing" OR "Quality control" OR "Capsid titration" OR "Empty-to-full ratio" OR "Host cell protein" OR "Replication-competent virus")
Biosafety and off-target profiling, combined via AND — ("Off-target cleavage" OR "Immunogenicity" OR "Biosafety" OR "Insertional mutagenesis")
This layered structure was designed to trace the full analytical and safety lifecycle of viral vector platforms—from initial vector design and payload delivery through to downstream quality control and biosafety evaluation—while reducing the likelihood of overlooking relevant work indexed under adjacent but non-identical terminology.

2.2 Selection Criteria

To keep the review technically focused, strict eligibility criteria were applied during the screening process (11,15).
Inclusion criteria:
Peer-reviewed studies addressing the characterization, purity testing, or safety profiling of viral vectors (6).
Experimental or clinical data concerning the viral delivery of targeted endonucleases (4).
Official regulatory frameworks and Good Manufacturing Practice (GMP) guidance relevant to cell and gene therapy products (15).
Mechanistic studies examining vector immunogenicity, host genomic insertion, or off-target nuclease activity (8).
Exclusion criteria:
Studies concerned solely with non-viral delivery systems, where no meaningful comparison to viral vectors was drawn.
Non-peer-reviewed preprints lacking complete analytical characterization data.
Reports that did not provide concrete methodological detail on vector yield, structural purity, or biosafety assessment (6).

2.3 Data Categorization and Synthesis

Each retrieved study was screened at the title, abstract, and full-text stages before inclusion (11). Data extracted from the final set of studies were then organized into three broad analytical domains, reflecting the natural structure of the field rather than an arbitrary classification scheme (6,8,13):
Physical and genomic integrity assays — covering vector yield determination, genome packaging efficiency, and impurity profiling (6,10,12).
Biological safety and replication competency — encompassing methods for detecting replication-competent viral revertants and assessing insertional risk (13).
Nuclease precision assays — addressing on-target editing efficiency alongside genome-wide off-target cleavage and structural chromosomal rearrangements (8,9).

3. ANALYTICAL TESTING STRATEGIES AND BIOSAFETY FRAMEWORKS

Bringing a clinical-grade viral vector carrying active genome-editing machinery to the point of regulatory acceptance calls for more than a single test or two—it requires an integrated analytical architecture that works across several dimensions simultaneously. Beyond the routine identity and potency assays that any biological product undergoes, a modern quality control program for these vectors must also characterize packaging efficiency, structural homogeneity, residual process-derived impurities, and the specific toxicity risks introduced by an active nuclease payload (6,8,15).

3.1 Capsid Titration and Empty-to-Full Ratio Resolution

One of the more consequential characterization tasks for recombinant AAV (rAAV) and lentiviral products is establishing what fraction of the total capsid population actually contains the intended genome, as opposed to being empty or only partially filled (6,7). This distinction matters clinically, not just academically: empty capsids contribute nothing therapeutically, yet they still carry the full antigenic burden of the capsid protein shell, which means they can drive host immune responses without offering any corresponding benefit (6,7).



Figure 1: outlines the orthogonal analytical strategy typically used to resolve this question.

Several complementary techniques are brought to bear on this problem:

Analytical Ultracentrifugation (AUC) remains the quantitative reference method of choice, distinguishing full, empty, and intermediate capsid species on the basis of their differing sedimentation coefficients (6).

Size-Exclusion Chromatography with Multi-Angle Light Scattering (SEC-MALS) offers a faster alternative, pairing dual-wavelength UV absorbance with refractive index measurement to estimate particle molar mass and, from that, average capsid filling percentage (6).

Droplet Digital PCR (ddPCR) is used for absolute quantification of packaged genomes (vg/mL). Unlike conventional qPCR, it does not depend on a standard curve and tends to hold up better in the presence of amplification inhibitors that are often present in complex biological matrices (10).

3.2 Impurity Profiling: Residual Host Elements and Helper Constructs

Large-scale vector production—whether carried out in human embryonic kidney (HEK293) cells or insect (Sf9) cell platforms—inevitably leaves behind trace amounts of host-derived material and helper plasmid DNA that can co-purify with the viral product itself. These residuals are not merely a purity concern; they carry genuine oncogenic and inflammatory risk if left unchecked (6,12). Table 1 summarizes the principal impurity categories encountered during manufacturing, along with the analytical methods used to detect them and the regulatory limits typically applied.

Table 1. Primary Process-Derived Impurities in Viral Vector Manufacturing, Associated Analytical Detection Strategies, and Regulatory Thresholds

Impurity Category	Primary Origin	Analytical Methodology	Regulatory Concern & Acceptance Limits
Host Cell Protein (HCP)	Producer cell line lysis (HEK293, Sf9)	ELISA, LC-MS/MS proteomic profiling	Anaphylactic and systemic inflammatory risks; target threshold generally <100 ng/dose (6,12).
Host Cell DNA (HCD)	Genomic fragmentation of host cells	Targeted qPCR, ddPCR, NGS profiling	Risk of insertional mutagenesis; strict regulatory ceiling of <10 ng/dose with fragment size <200bp (6,10,15).
Residual Plasmid DNA	Unincorporated transfection plasmids	Sequence-specific ddPCR	Potential horizontal transfer of bacterial sequences or antibiotic resistance genes (6,10,12,15).

3.3 Biosafety Protocols: Testing for Replication-Competent Recombinants

For integrating vector platforms in particular—retroviral and lentiviral systems especially—one of the non-negotiable safety requirements is demonstrating the complete absence of Replication-Competent Lentivirus (RCL) or Retrovirus (RCR) in the final product (13). These unwanted recombinants arise, albeit rarely, through homologous recombination between the helper packaging constructs and the vector backbone during upstream production, and their detection requires dedicated assays rather than incidental screening (13).

Two complementary approaches are generally employed:

Cell-culture-based amplification assays, in which product samples are serially passaged across sensitive indicator cell lines—C8166 or HeLa cells, for example—over a period of 21 to 28 days. This extended passaging is designed to amplify even very low-level replication-competent contaminants to detectable levels, after which p24 antigen ELISA or quantitative PCR is used to confirm their presence or absence (13).

Envelope-specific PCR assays, which molecularly confirm that structural envelope genes—vesicular stomatitis virus G glycoprotein (VSV-G) being a common example—are not present outside their intended helper-construct context (13).

3.4 Evaluation of Off-Target Nuclease Activity and Genomic Instability

Once a viral vector is tasked with delivering an active gene-editing endonuclease such as Cas9, safety testing has to move well beyond physical vector characterization and into the realm of genomic editing specificity within target cell populations (8,15). This becomes particularly important given that AAV vectors often persist episomally over extended periods, meaning sustained nuclease expression can steadily increase the cumulative risk of off-target cleavage over time rather than posing a one-time risk (3,8,9).



Figure 2: lays out the general analytical pipeline used to assess both on-target efficiency and off-target mutagenesis in this context.

Unbiased, genome-wide identification of potential off-target sites typically relies on:

GUIDE-seq, which captures double-strand breaks in living cells by incorporating short double-stranded oligodeoxynucleotide tags directly at cleavage sites during the cell's own repair process (8).

CIRCLE-seq and CHANGE-seq, cell-free in vitro methods that screen purified genomic DNA against candidate endonuclease target sites across the entire genome, typically as a precursor to cell-based confirmatory testing (8).

Once candidate off-target loci have been flagged through these unbiased screens, more targeted quantification follows:

Deep amplicon sequencing is used to measure insertion-deletion (indel) frequencies at these loci with next-generation sequencing depth sufficient to detect events occurring at frequencies below 0.1% (8,9).

Chromosomal rearrangement profiling addresses a different but related concern: large structural variants, inversions, or translocations that can arise when multiple double-strand breaks occur simultaneously. This is typically assessed using long-read sequencing platforms such as Oxford Nanopore or PacBio, alongside more traditional cytogenetic methods like FISH and karyotyping (8,15).

4. CONCLUSION AND FUTURE DIRECTIONS

4.1 Conclusion

Genetic medicine now finds itself at a genuinely pivotal stage of its development. The move away from simple gene addition toward site-specific genomic repair, carried out through viral delivery systems, demands that analytical testing evolve in step with it—not lag behind, and not simply borrow methods designed for an earlier generation of therapeutic products. Viral platforms, recombinant AAV and lentiviral vectors chief among them, continue to serve as the workhorses for delivering both conventional therapeutic transgenes and the more complex endonuclease systems now entering the clinic. Yet none of this translates into clinical success unless vector identity, structural purity, and genomic safety are characterized with real precision; there is little room for approximation here.

Building a quality control framework capable of meeting that standard means weaving together several distinct testing strands rather than treating them as separate checkboxes. Capsid filling fractions need to be resolved through techniques such as AUC and SEC-MALS; residual host-derived contaminants need to be quantified with equal rigor; and the absence of replication-competent viral recombinants must be confirmed, not assumed. Where a vector is tasked with delivering an active endonuclease, the testing burden grows further still—genomic safety assessment becomes essential, encompassing off-target cleavage rates, structural chromosomal rearrangements, and the immune responses that vector components themselves can provoke. Bringing these analytical criteria under a common, standardized framework is not simply a matter of regulatory convenience; it is what ultimately safeguards patients across the full range of clinical applications these therapies are intended to reach.

4.2 Future Directions

Looking ahead, several developments seem likely to reshape how viral vectors are characterized in the coming years:

- **In-line Process Analytical Technology (PAT).** The field is gradually moving away from testing that happens only after a production lot is complete, toward real-time monitoring built directly into the bioreactor process itself. As spectroscopic sensors and automated analytical modules become more integrated into manufacturing lines, continuous tracking of vector titer, capsid assembly, and impurity formation as they happen—rather than after the fact—should become increasingly feasible.
- **Single-cell multi-omics profiling.** Bringing single-cell DNA and RNA sequencing into routine safety evaluation stands to improve resolution considerably, particularly for detecting low-frequency off-target mutations, structural variants, and transcriptional shifts that can otherwise be masked within a heterogeneous cell population.
- **Transient and self-inactivating nuclease designs**. Given that prolonged endonuclease expression—especially from long-lived episomal AAV constructs—raises cumulative off-target risk over time, vector systems are likely to shift increasingly toward self-limiting or transient expression architectures. This shift will, in turn, require analytical methods capable of characterizing how quickly and reliably nuclease activity actually clears from target tissues.
- **Global regulatory harmonization.** As guidance from the FDA, EMA, and international standards bodies continues to mature, the field will need validated reference standards and harmonized testing protocols to support multi-center clinical trials and eventual commercial adoption of viral vector-mediated gene editing therapies on a global scale.

FUNDING INFORMATION: The author states that no funding was involved in this study.

AUTHOR CONTRIBUTION STATEMENT: Author Contributions: All authors contributed equally to this work, including the conceptualization and design of the study, execution of laboratory procedures, analysis and interpretation of the resulting data, and drafting and critical revision of the manuscript. All authors have reviewed the final version of the manuscript and approved it for submission.

CONFLICT OF INTEREST STATEMENT: The author declares that there are no conflicts of interest or competing financial interests regarding the publication of this review paper.

INFORMED CONSENT: None.

ETHICAL APPROVAL: As a review paper, this study did not involve direct experimental work with human participants, animals, or field-specific environmental hazards. All research procedures nonetheless comply with the academic integrity guidelines established by the Ministry of Higher Education and Scientific Research in Iraq.

DATA AVAILABILITY: No new data were created or analyzed in this study. All data sources evaluated and discussed are cited within the article.

REFERENCES

1) Alisha M Gruntman, Terence R Flotte. The rapidly evolving state of gene therapy. *The FASEB Journal,* April 2018;32(4): 1733-1740. **https://doi.org/10.1096/fj.201700982R**
2) Doudna JA. The promise and challenge of therapeutic genome editing. *Nature*. 2020;578(7794):229-236. https://www.nature.com/articles/s41586-020-1978-5
3) Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. *Nat Rev Drug Discov*. 2019;18(5):358-378. https://www.nature.com/articles/s41573-019-0012-9
4) Cox DBT, Platt RJ, Zhang F. Therapeutic genome editing: prospects and challenges. *Nature Medicine*. 2015;21(2):121-131. https://www.nature.com/articles/nm.3793
5) Milone MC, O'Doherty U. Clinical use of lentiviral vectors. *Leukemia*. 2018;32(7):1529-1541. https://www.nature.com/articles/s41375-018-0106-0
6) Wright JF. Quality control testing for clinical grade AAV vectors. *Gene Ther*. 2008;15(11):840-848. https://www.nature.com/articles/gt200865
7) Schnödt M, Büning H. Improving the quality and safety of AAV vectors for clinical applications. *Expert Opin Biol Ther*. 2017;17(8):989-999.
8) Tsai SQ, Joung JK. Defining and improving the genome-wide specificities of CRISPR-Cas nucleases. *Nat Rev Genet*. 2016;17(5):300-312. https://www.nature.com/articles/nrg.2016.28
9) Kleinstiver BP, Pattanayak V, Prew MS, et al. High-fidelity CRISPR-Cas9 nucleases with undetectable genome-wide off-target effects. *Nature*. 2016;529(7587):490-495. https://www.nature.com/articles/nature16526
10) Dobnik D, Kogovšek P, Jakomin T, et al. Accurate Quantification and Characterization of Adeno-Associated Viral Vectors. *Front Microbiol*. 2019;10:1570. https://doi.org/10.3389/fmicb.2019.01570
11) Ginn SL, Amaya AK, Alexander IE, Edelstein M, Abedi MR. Gene therapy clinical trials worldwide to 2017: An update. *J Gene Med*. 2018;20(5):e3015. https://doi.org/10.1002/jgm.3015
12) Rumachik NG, Malaker SA, Poweleit N, et al. Methods Matter: Standard Production Platforms for Recombinant AAV Produce Chemically and Functionally Distinct Vectors. Mol Ther Methods *Clin Dev*. 2020;18:98-118. https://www.addgene.org/browse/article/28196761/
13) Skrdlant LM, Armstrong RJ, Zhang C, et al. Detection of replication-competent lentivirus using a secondary functional assay for viral envelope protein. Mol Ther Methods *Clin Dev*. 2020;18:475-483. DOI: 10.1016/j.omtm.2017.09.001
14) Anzalone AV, Randolph PB, Davis JR, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. *Nature*. 2019;576(7785):149-157. https://www.nature.com/articles/s41586-019-1711-4
15) U.S. Food and Drug Administration (FDA). *Human Gene Therapy Products Incorporating Human Genome Editing; Guidance for Industry*. Silver Spring, MD: U.S. Department of Health and Human Services; 2023. https://hdl.handle.net/102.100.100/494750